Listen
RYEQO (relugolix/estradiol/norethisterone acetate) - Endometriosis, uterine, fibroids
Opinions on drugs -
Posted on
Oct 31 2024
Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement in:
- the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis,
- treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
No clinical added value of the new form compared to the forms already available.
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of RYEQO (relugolix/estradiol/norethisterone acetate) is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed. |
